Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 08
2023
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
4,200
-1.07%
|
-
|
|
Feb 01
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
7,035
-7.47%
|
$2,420,040
$344.15 P/Share
|
|
Feb 01
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
15,675
+14.26%
|
-
|
|
Feb 01
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
3,252
-5.64%
|
$1,118,688
$344.15 P/Share
|
|
Feb 01
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
7,264
+11.2%
|
-
|
|
Feb 01
2023
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
941
-2.91%
|
$323,704
$344.15 P/Share
|
|
Feb 01
2023
|
Johna Norton EVP, Global Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
2,102
+6.1%
|
-
|
|
Feb 01
2023
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,438
-4.89%
|
$494,672
$344.15 P/Share
|
|
Feb 01
2023
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,154
+9.69%
|
-
|
|
Feb 01
2023
|
Michael B Mason EVP & Pres., Lilly Diabetes |
SELL
Payment of exercise price or tax liability
|
Direct |
2,935
-8.58%
|
$1,009,640
$344.15 P/Share
|
|
Feb 01
2023
|
Michael B Mason EVP & Pres., Lilly Diabetes |
BUY
Exercise of conversion of derivative security
|
Direct |
6,690
+16.36%
|
-
|
|
Feb 01
2023
|
Anat Hakim EVP, GC & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,393
-20.55%
|
$1,167,192
$344.15 P/Share
|
|
Feb 01
2023
|
Anat Hakim EVP, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,646
+31.65%
|
-
|
|
Feb 01
2023
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,997
-7.88%
|
$1,030,968
$344.15 P/Share
|
|
Feb 01
2023
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
BUY
Exercise of conversion of derivative security
|
Direct |
6,690
+14.95%
|
-
|
|
Feb 01
2023
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,359
-5.17%
|
$7,347,496
$344.15 P/Share
|
|
Feb 01
2023
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,786
+10.37%
|
-
|
|
Jan 17
2023
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.87%
|
$4,998
$357.74 P/Share
|
|
Jan 17
2023
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.01%
|
$2,142
$357.74 P/Share
|
|
Jan 17
2023
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+4.51%
|
$9,996
$357.74 P/Share
|
|
Jan 17
2023
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+0.27%
|
$14,280
$357.74 P/Share
|
|
Jan 17
2023
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27
+1.34%
|
$9,639
$357.74 P/Share
|
|
Jan 17
2023
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+0.04%
|
$9,996
$357.74 P/Share
|
|
Jan 17
2023
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
32
+0.06%
|
$11,424
$357.74 P/Share
|
|
Dec 19
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
32
+0.06%
|
$11,424
$357.78 P/Share
|
|
Dec 19
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+0.04%
|
$9,996
$357.78 P/Share
|
|
Dec 19
2022
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+4.72%
|
$9,996
$357.78 P/Share
|
|
Dec 19
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27
+1.36%
|
$9,639
$357.78 P/Share
|
|
Dec 19
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
39
+0.26%
|
$13,923
$357.78 P/Share
|
|
Dec 19
2022
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+1.74%
|
$9,996
$357.78 P/Share
|
|
Dec 02
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
49,089
-0.01%
|
$18,261,108
$372.97 P/Share
|
|
Dec 01
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
160,911
-0.03%
|
$60,019,803
$373.31 P/Share
|
|
Nov 21
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
525
+0.37%
|
$189,525
$361.17 P/Share
|
|
Nov 21
2022
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
359
+24.97%
|
$129,599
$361.17 P/Share
|
|
Nov 21
2022
|
Karen Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+8.28%
|
$179,778
$361.17 P/Share
|
|
Nov 21
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
525
+11.22%
|
$189,525
$361.17 P/Share
|
|
Nov 21
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
537
+1.78%
|
$193,857
$361.17 P/Share
|
|
Nov 21
2022
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
525
+13.38%
|
$189,525
$361.17 P/Share
|
|
Nov 21
2022
|
Katherine Baicker Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+2.2%
|
$179,778
$361.17 P/Share
|
|
Nov 21
2022
|
Jamere Jackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+5.62%
|
$179,778
$361.17 P/Share
|
|
Nov 21
2022
|
William G Kaelin Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+2.38%
|
$179,778
$361.17 P/Share
|
|
Nov 21
2022
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+0.78%
|
$179,778
$361.17 P/Share
|
|
Nov 21
2022
|
Marschall S Runge Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+3.0%
|
$179,778
$361.17 P/Share
|
|
Nov 21
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
529
+0.5%
|
$190,969
$361.17 P/Share
|
|
Nov 07
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
63,585
-0.01%
|
$23,144,940
$364.42 P/Share
|
|
Nov 04
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
1,336
-0.0%
|
$484,968
$363.73 P/Share
|
|
Nov 03
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
133,948
-0.13%
|
$48,489,176
$362.08 P/Share
|
|
Nov 02
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
6,131
-0.01%
|
$2,219,422
$362.07 P/Share
|
|
Oct 21
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
161,936
-0.02%
|
$54,734,368
$338.9 P/Share
|
|
Oct 19
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
3,547
-0.0%
|
$1,188,245
$335.48 P/Share
|